Exclusive: Two ex-Recursion leaders start Noetik in a bid to fix the broken funnel in cancer drug research

Andrew Dunn

Senior Biopharma Correspondent

Two former leaders of Recursion Pharmaceuticals have started their own biotech startup, hoping to bring a similar data-obsessed mentality to cancer research.

The San Francisco …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Exclusive: Two ex-Recursion leaders start Noetik in a bid to fix the broken funnel in cancer drug research

Andrew Dunn

Senior Biopharma Correspondent

Sign up to read this article for free.

Uro-Oncology Business Manager

ImmunityBio, Inc.

Remote

Biotech seed rounds sink to lowest level in years as industry slump drags on

US drugs rely heavily on ingredients made overseas, new report shows

Pharma's wins and losses in Trump's sprawling executive order on drug prices

Eli Lilly reports first Phase 3 data for oral GLP-1, posting a win in diabetes

Exclusive: VelaVigo inks another US biotech deal as China drug development scene booms

New York-based partnership sets the standard for expanding clinical trial access for underserved and diverse ...

Ex­clu­sive: Two ex-Re­cur­sion lead­ers start Noetik in a bid to fix the bro­ken fun­nel in can­cer drug re­search

Senior Biopharma Correspondent

Sign up to read this article for free.

ImmunityBio, Inc.

Remote

Exclusive: Two ex-Recursion leaders start Noetik in a bid to fix the broken funnel in cancer drug research